Sosenko Piscitello, Anastasia
Nilsson, Ann-Sofie
Hawgood, Michael https://orcid.org/0000-0003-3886-7534
Sayyid, Abid H. https://orcid.org/0009-0001-7956-8947
Dionellis, Vasilis S.
Giglio, Giovanni https://orcid.org/0009-0009-0349-3756
Urién, Bruno https://orcid.org/0009-0006-8205-6578
Bajgain, Pratikiran https://orcid.org/0009-0003-0686-3253
Ntallis, Sotirios G. https://orcid.org/0000-0002-6093-8979
Bartek, Jiri https://orcid.org/0000-0003-2013-7525
Halazonetis, Thanos D. https://orcid.org/0000-0001-8384-5030
Lemmens, Bennie https://orcid.org/0000-0001-8051-1676
Funding for this research was provided by:
Vetenskapsrådet
Cancerfonden
Karolinska Institutet
The Mark Foundation for Cancer Research
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Article History
Received: 10 December 2024
Accepted: 21 August 2025
First Online: 12 September 2025
Competing interests
: T.D.H. is the founder and stockholder of FoRx Therapeutics. The remaining authors declare no competing interests.